Condition: Breast Cancer · Sponsor: Shanghai Jiao Tong University School of Medicine
The overarching purpose of this study is to determine if the mainstay chemotherapeutic regimens represented by several genotoxic agents including but not limited to Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil and Methotrexate (CDEFM), in the format of either a single agent or combinations are safe, tolerable, and effective in the treatment of patients with infiltrating ductal carcinoma of breast.
This description comes directly from the study's public registry record.
Yu Sun, Ph.D · 86-21-54923302 · sunyu@sibs.ac.cn
Always discuss trial participation with your own doctor first.
| Ganzhou City People's Hospital | Ganzhou, Jiangxi, China | Recruiting |
| China-Japan Union Hospital, Jilin University | Changchun, Jilin, China | Recruiting |
| Shanghai 10th People's Hospital, Tongji University School of Medicine | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02897700